Genetic Variation in the Glucocorticoid Pathway Involved in Interindividual Differences in the Glucocorticoid Treatment
The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases. However, in a subgroup of patients, failure to respond to GCs is known as GC resistance or GC insensitivity. This represents an important barrier to effective treatment and a clinical problem requiring an urgent solution. Genetic variation in the GC pathway is a significant factor in interindividual differences in GC treatment. This article reviews the pharmacogenetics of GCs in diverse diseases based on the GC pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The underlying mechanisms of action can be different, ranging from pharmacokinetic and pharmacodynamic properties of the used drugs to genetic predisposition [85].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [85]
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J.-F., Gasche, C., Geboes, K., et al. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/269076 · Cited by 3,409
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Self-citationSteroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Hench, P. S., Kendall, E. C., Slocumb, C. H., & Polley, H. F. (1949) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00526-3 · Cited by 1,179
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.9 · Cited by 966
Research works printed but not linked: 4
- 10.1210/jcem.87.4.8379 · doi:10.1210/jcem.87.4.8379 · Paper page
- 10.1210/jcem.87.6.8520 · doi:10.1210/jcem.87.6.8520 · Paper page
- 10.1016/s0140-6736(04)15650-x · DOI · Paper page
- 10.3109/s10165-004-0354-x · doi:10.3109/s10165-004-0354-x
Cited by
Stress and Obesity: Are There More Susceptible Individuals?
van der Valk, E. S., Savas, M., & van Rossum, E. F. C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0306-y · Cited by 402
Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis
Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102201 · Cited by 181
“The underlying mechanisms of action can be different, ranging from pharmacokinetic and pharmacodynamic properties of the used drugs to genetic predisposition [85].”
BackgroundChronopharmacology of glucocorticoids
Scherholz, M. L., Schlesinger, N., & Androulakis, I. P. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.004 · Cited by 144
Autry, R. J., Paugh, S. W., Carter, R., Shi, L., Liu, J., Ferguson, D. C., Lau, C. E., Bonten, E. J., Yang, W., McCorkle, J. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0037-3 · Cited by 85
Self-citationDisease-drug and drug-drug interaction in COVID-19: Risk and assessment
Kumar, D., & Trivedi, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111642 · Cited by 84
“have been associated with corticosteroid response across multiple disease condition [189].”
Pharmacogenomics of COVID-19 therapies
Takahashi, T., Luzum, J. A., Nicol, M. R., & Jacobson, P. A. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-00143-y · Cited by 83
Advances in treatment of glucocorticoid-induced osteoporosis
Hsu, E., & Nanes, M. S. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000368 · Cited by 56
“Individual sensitivity to glucocorticoid signalling is also affected by genetic variability of the glucocorticoid receptor, with alternative splicing and polymorphisms identified [15,16].”
Variation in glucocorticoid sensitivity and the relation with obesity
Lengton, R., Iyer, A. M., van der Valk, E. S., Hoogeveen, E. K., Meijer, O. C., van der Voorn, B., & van Rossum, E. F. C. (2021) · Obesity Reviews · doi:10.1111/obr.13401 · Cited by 50
The clinical significance of the glucocorticoid receptors: Genetics and epigenetics
Motavalli, R., Majidi, T., Pourlak, T., Abediazar, S., Shoja, M. M., Vahed, S. Z., & Etemadi, J. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105952 · Cited by 42
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
Biswas, M., Sawajan, N., Rungrotmongkol, T., Sanachai, K., Ershadian, M., & Sukasem, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835136 · Cited by 35
“, MDR1 and ABCB1) may have various genetic polymorphisms accounting for modulating the safety or efficacy of corticosteroids (Song et al., 2017).”
BackgroundAL-Eitan, L. N., & Alahmad, S. Z. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2194 · Cited by 32
Li, J., Hua, M., Hu, X., Zhang, Y., Feng, Q., Qiu, J., Shao, L., Li, N., Hou, M., & Peng, J. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.004 · Cited by 25
Cazzola, M., Rogliani, P., Calzetta, L., & Matera, M. G. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s231471 · Cited by 25
Pharmacogenetic Perspective for Optimal Gout Management
Alrajeh, K., & Roman, Y. M. (2022) · Future Pharmacology · doi:10.3390/futurepharmacol2020011 · Cited by 20
Lucafò, M., Sicari, D., Chicco, A., Curci, D., Bellazzo, A., Silvestre, A. D., Pegolo, C., Autry, R. J., Cecchin, E., Iudicibus, S. D., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04122-z · Cited by 15
Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
Bárcenas-López, D. A., Mendiola-Soto, D. K., Núñez-Enríquez, J. C., Mejía‐Aranguré, J. M., Hidalgo‐Miranda, A., & Jiménez‐Morales, S. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100978 · Cited by 15
“ng their relevance in the pharmacogenomics field [61] .”
BackgroundBurgueño‐Rodríguez, G., Méndez, Y., Olano, N., Schelotto, M., Castillo, L. A., Soler, A., & da Luz, J. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1278769 · Cited by 12
“ABCB1 protein is a drug ef fl ux pump with broad substrate speci fi city that can expulse PRED, VCR, MTX, and anthracyclines to the extracellular space (Gregers et al., 2015; Song et al., 2017).”
BackgroundFlores, C. H., Marcos, M., Carbonell, C., Canelo, J. A. M., Espinosa, G., Cervera, R., & Fernández, A. J. C. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.034 · Cited by 13
Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?
Franczyk, B., Rysz, J., Miłoński, J., Konecki, T., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2022) · Pharmaceuticals · doi:10.3390/ph15060739 · Cited by 11
Synthesis and Hypoglycemic Activity of New Nicotinonitrile-Furan Molecular Hybrids
Tilchenko, D. A., Bibik, E. Y., Dotsenko, V. V., Krivokolysko, S. G., Фролов, К. А., Aksenov, N. A., & Aksenova, I. V. (2024) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162024020183 · Cited by 10
Chronic Stress Related to Cancer Incidence, including the Role of Metabolic Syndrome Components
Pham, A. T., van Dijk, B. A. C., van der Valk, E. S., van der Vegt, B., van Rossum, E. F. C., & de Bock, G. H. (2024) · Cancers · doi:10.3390/cancers16112044 · Cited by 10
“In addition to stress, other factors that can influence systemic cortisol levels include the glucocorticoid gene [61], inflammation [62], medications use (corticosteroids), food with a high glycemic index [63], chronic pain [64], sleep deprivation [65], alcohol [66], and night-eating syndrome [67].”
BackgroundPharmacogenetic and pharmacogenomic considerations of asthma treatment
Matera, M. G., Rinaldi, B., Calzetta, L., & Cazzola, M. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1391215 · Cited by 10
Ramayanam, N. R., Amarnath, R. N., Ramasamy, M., & Vijayakumar, T. M. (2023) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2023.90044 · Cited by 9
Kong, Y., Ding, L., Xu, Y. C., Wang, Z., & Sun, L. (2020) · Pharmacology · doi:10.1159/000504516 · Cited by 9
GENETIC PREDICTORS OF SEVERITY AND EFFICACY OF COVID-19 PHARMACOTHERAPY
Shishimorov, I., Magnitskaya, O. V., & Пономарева, Ю. В. (2021) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2021-9-3-174-184 · Cited by 7
“Однако, возможные варианты фармакологического ответа могут быть связаны с рецепторной активностью, а также фармакокинетических путей через активность ферментов метаболизма и белков-транспортеров [52].”
Wang, B., Tang, L., Shi, S., Yang, Y., Sun, X., Zhang, X., Liu, C., & Liu, L. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1525110 · Cited by 7
“At present, glucocorticoid drugs are still the first-line medication for the management of asthma; however, the safety issue remains to be solved, and whether glucocorticoid medications could fundamentally reduce the process of airway remodeling remains further investigation [4, 5].”
BackgroundUnraveling the Impact of Salbutamol Polytherapy: Clinically Relevant Drug Interactions
Marques, L., & Vale, N. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010019 · Cited by 7
Lee, H. S., Park, H., & Lee, S. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00480 · Cited by 4
Cavalcante, P., Mantegazza, R., & Bernasconi, P. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1804865 · Cited by 4
Thomas, J. K., & Thomson, E. M. (2021) · Toxics · doi:10.3390/toxics9110290 · Cited by 4
“Glucocorticoid signalling in target tissues is, in turn, mediated primarily through binding to receptors; moreover, there is significant inter-individual variability in GR expression, and chronic impairment in GR function can lead to lung glucocorticoid resistance [35,36].”
BackgroundMeduri, G. U. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2691-6206 · Cited by 3
“22 Incorporating antioxidant agents into treatment protocols may improve steroid responsiveness and clinical outcomes in patients with oxidative stress-driven GCR. preserving GC-GR α signaling, antioxidant co-therapies contribute to restoring mitochondrial integrity and systemic homeostasis.”
Bazsó, A., Szappanos, Á., Kövesdi, A., Rásonyi, R., Nagy, E., Patócs, A., Poór, G., & Kiss, E. V. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102362 · Cited by 3
Prazosin Protects the Liver Against Renal Ischemia/Reperfusion Injury in Rats
Khajepour, F., Mahmoodpoor, F., Jafari, E., Kakaei, F., Bahraminia, F., Aghajani, S., Vahed, S. Z., & Bagheri, Y. (2023) · Drug Research · doi:10.1055/a-2015-7976 · Cited by 2
“However, tamsulosin, another α-adrenoreceptor blocker, had no direct protective effect on liver tissue damage induced by D-galactosamine [27].”
BackgroundGene Influencing in COVID-19 Infection, Disease Severity and its Pharmacotherapy
Sarkar, S., Dasgupta, S., Srivastava, V., Sahoo, S., & Tripathi, S. K. (2021) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2021.sp178 · Cited by 1
Precision medicine: recent advances, current challenges and future perspectives
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5042-7 · Cited by 1
Iatrogénie et syndromes de Cushing
Ruellan, A., & Boels, D. (2019) · Actualités Pharmaceutiques · doi:10.1016/j.actpha.2019.02.006
Enabling personalized medicine through pharmacokinetic modeling
Scherholz, M. L. (2019) · doi:10.7282/t3-2ry2-4f60
Glucocorticoids and Musculoskeletal Health
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_31
NR3C1 gene polymorphisms in adult patients with nephrotic syndrome
Ahmadian, E., Hejazian, S. M., Vahedi, L., Khakpour, A., Jalalat, J., Vahed, S. Z., & Ardalan, M. (2021) · Journal of Renal Injury Prevention · doi:10.34172/jrip.2022.29849
“The GR as a cytoplasmic receptor is activated after the binding of steroids and stimulates the transcription of gene classes that hamper inflammatory cytokines and enhance anti-inflammatory mediators (7).”
BackgroundKapfhammer, H. (2022) · Springer eBooks · doi:10.1007/978-3-662-65873-4_4
Synthesis and hypoglycemic activity of new nicotinonitrile-furan molecular hybrids
Tilchenko, D. A., Bibik, E. Y., Dotsenko, V. V., Krivokolysko, S. G., Фролов, К. А., Aksenov, N. A., & Aksenova, I. V. (2024) · Биоорганическая химия · doi:10.31857/s0132342324020068
Komino, A. C. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2023.tde-07082025-145857
Burgueño‐Rodríguez, G. (2022) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Burgueño-Rodríguez, G., Méndez, Y., Olano, N., Schelotto, M., Castillo, L., Soler, A. M., & da Luz, J. (2023) · doi:10.3389/fphar.2023.1278769.s006
Metadata
- Authors
- Song, Q.-Q., Xie, W.-Y., Tang, Y.-J., Zhang, J., & Liu, J.
- Affiliations
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha410008, Hunan, P.R. China
- Central South University (CN)
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2017-01-23
- Volume
- 18
- Issue
- 3
- Pages
- 293-316
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2583071148
- Cited by
- 40
- References
- 170
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 10 · 2019: 4 · 2018: 2 · 2017: 3
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation (81070902, 30600774)
- China Postdoctoral Science Foundation (201104515, 2012M510138)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- glucocorticoids, glucocorticoid resistance, pharmacogenetics, genetic variation, glucocorticoid pathway, interindividual variability, glucocorticoid treatment response, autoimmune disease
- MeSH terms
- Autoimmune Diseases, Glucocorticoids, Humans, Genetic Variation, Signal Transduction, Treatment Outcome, Polymorphism, Single Nucleotide, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.